Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial.
about
A comprehensive review of lenalidomide in B-cell non-Hodgkin lymphomaLymphoma Immunotherapy: Current StatusImmune Modulation in Hematologic MalignanciesNext-generation prognostic assessment for diffuse large B-cell lymphomaNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewEvolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent updateLymphoma: immune evasion strategiesLenalidomide for the treatment of B-cell lymphoma.Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research.Emerging uses of patient generated health data in clinical research.L-PROBe: A Novel Non-anthracycline Combination Chemotherapy Regimen for Aggressive B Cell Non-Hodgkin Lymphoma in Elderly Patients.Lenalidomide in heavily pretreated refractory diffuse large B-cell lymphoma: a case reportDiffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosisExpanding role of lenalidomide in hematologic malignanciesEpstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma in the Elderly: A Matched Case-Control Analysis.Lenalidomide alone or in combination with chemotherapy treatment for subtypes of diffuse large B cell lymphoma: a systematic review and meta-analysis.A clinician's guide to double hit lymphomas.A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphomaThe preclinical discovery of rituximab for the treatment of non-Hodgkin's lymphoma.Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin LymphomaNovelties in the management of B-cell malignancies: B-cell receptor signaling inhibitors and lenalidomide.Is now the time for molecular driven therapy for diffuse large B-cell lymphoma?Clinical Impact of the 2016 Update to the WHO Lymphoma Classification.An update for Richter syndrome - new directions and developments.High rate of event-free survival at 24 months with everolimus/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance).Diffuse Large B-cell lymphoma: Prognostic markers and their impact on therapy.Epstein-Barr virus-associated diffuse large B-cell lymphoma: diagnosis, difficulties and therapeutic options.The evolving role of lenalidomide in non-Hodgkin lymphoma.Clinical experience with lenalidomide alone or in combination with rituximab in indolent B-cell and mantle cell lymphomas.EBV-positive diffuse large B-cell lymphoma of the elderly: 2016 update on diagnosis, risk-stratification, and management.Double hit lymphoma: from biology to therapeutic implications.Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells.The landscape of new drugs in lymphomaLenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group.Four doses of unpegylated versus one dose of pegylated filgrastim as supportive therapy in R-CHOP-14 for elderly patients with diffuse large B-cell lymphoma.A phase II randomized study of lenalidomide or lenalidomide and rituximab as maintenance therapy following standard chemotherapy for patients with high/high-intermediate risk diffuse large B-cell lymphoma.Drug Discovery by Molecular Imaging and Monitoring Therapy Response in Lymphoma.Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities.Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial.
P2860
Q26738937-9745C23D-338F-4F6A-AEF1-A56E2A39AF20Q26782902-942D6A00-B275-44DA-BEF4-6F8F28AF5973Q26796307-14B543FA-9C31-4965-9F00-64AEB42A507CQ26796428-F699F4A6-0184-4877-B47E-D9685C3E9E31Q27304386-0A164C69-F561-4AC3-BB0A-A23226F2D7B8Q28078869-E7582737-3644-4BED-A0E7-BF706E87B4F3Q28080705-99BAD0BB-D80F-4F34-9FE8-CC93D009BB1BQ30249007-849C47DA-7882-413D-992D-013D3DDEC4F5Q30275206-C6C9343F-2009-4206-A084-F5A4A9A10A73Q30854718-EF316D90-3754-4848-A9C0-54BA9C24B861Q33439291-FC99B8FD-E7A5-49A5-BC2D-6960C42CCE67Q34314074-43B582E0-4B19-4AB6-B0B0-39CFAB5E8802Q35419876-AACA9F49-2697-47FD-8202-8AD0F958C997Q35592305-D3E3CF24-D13C-49C2-95B6-7E92B7B8B551Q35723777-FB62F2D6-EFA4-48C6-8D4F-52F63DF462A0Q36046230-7DA61A16-BA80-4444-B909-18BABF96DEC5Q38296091-27F2A0F7-B675-4DE3-990D-498A4C57BAB8Q38364912-16B483EC-9104-4EC9-A784-115C23B74482Q38408414-5BDF1A9F-AE88-420F-82E0-C97F6C00249DQ38530254-800357D7-C1D1-44E7-A709-C6C02D63F312Q38551337-3804A9C8-629D-4117-8C4A-05E1A1EFBBBDQ38594364-81A284FF-BEF6-4FFD-A116-09B4A46B9383Q38656983-2838D93D-3AC9-4827-BF3C-6CF10ADB8C2EQ38663689-6A6492CA-5AED-40DD-A498-44DB96137E87Q38691261-7FAF399A-6964-4AD1-BBB7-9ABA92C8CE0EQ38709312-BD410430-EA62-478B-933B-4A4DB0A75BFAQ38710832-0D33730E-EBF6-4EEE-A33C-CE1647C456D0Q38720593-B6E75883-789E-4C34-8DEB-A8FDC85CABFCQ38744704-478D7F79-3D27-4668-A649-F2260BC77AEEQ38800049-46B8CB00-26A8-46B5-A1FB-59379CE7494FQ38812004-F6091ED3-F663-4A7D-9C42-D0B3CFAEDF81Q38831667-28E79241-929F-471C-AD09-C7B2BFC8D937Q38889427-FC5253BD-58A7-45F1-8EBF-2BD4AFBA022FQ39061630-6862BAF3-03F6-4935-9FB5-80F6852F6F85Q40022297-2130C381-D7EE-4B9B-811C-62AEF58CC52BQ40163155-482D7CD3-7E96-46CE-BA5B-544A6F0D26CBQ40778810-A661E210-13B9-4864-89A9-BFC2FE940025Q41573147-8DE3729D-395F-44BE-8D46-61DE0A2A8383Q42087653-58FDA060-0B33-43EE-8395-4EF82B5DA6D7Q47776008-668C16CF-6FD4-4848-A146-A0B95171C5D7
P2860
Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Lenalidomide plus R-CHOP21 in ...... l, multicentre, phase 2 trial.
@ast
Lenalidomide plus R-CHOP21 in ...... l, multicentre, phase 2 trial.
@en
type
label
Lenalidomide plus R-CHOP21 in ...... l, multicentre, phase 2 trial.
@ast
Lenalidomide plus R-CHOP21 in ...... l, multicentre, phase 2 trial.
@en
prefLabel
Lenalidomide plus R-CHOP21 in ...... l, multicentre, phase 2 trial.
@ast
Lenalidomide plus R-CHOP21 in ...... l, multicentre, phase 2 trial.
@en
P2093
P50
P1433
P1476
Lenalidomide plus R-CHOP21 in ...... l, multicentre, phase 2 trial.
@en
P2093
Alessia Castellino
Alfonso Zaccaria
Angela Congiu
Angelo Michele Carella
Anna Lia Molinari
Anna Marina Liberati
Barbara Botto
Flavia Salvi
Fondazione Italiana Linfomi
Giorgio Inghirami
P304
P356
10.1016/S1470-2045(14)70191-3
P50
P577
2014-05-13T00:00:00Z